Elevance Health (NYSE:ELV) Upgraded by Wall Street Zen to “Buy” Rating

Elevance Health (NYSE:ELV) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday.

Several other equities research analysts have also issued reports on ELV. Barclays lowered their price target on shares of Elevance Health from $404.00 to $393.00 and set an “overweight” rating on the stock in a report on Friday. Zacks Research raised shares of Elevance Health from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 6th. Morgan Stanley dropped their price target on shares of Elevance Health from $359.00 to $352.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 17th. Weiss Ratings raised Elevance Health from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, January 12th. Finally, Guggenheim lowered their price objective on Elevance Health from $414.00 to $396.00 and set a “buy” rating on the stock in a research note on Thursday. Twelve analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, Elevance Health currently has an average rating of “Moderate Buy” and an average target price of $398.16.

Elevance Health Trading Down 0.4%

Shares of ELV opened at $345.62 on Friday. The stock’s 50-day moving average price is $351.69 and its 200 day moving average price is $329.03. The company has a quick ratio of 1.56, a current ratio of 1.54 and a debt-to-equity ratio of 0.70. The firm has a market capitalization of $76.81 billion, a price-to-earnings ratio of 13.76, a P/E/G ratio of 1.88 and a beta of 0.51. Elevance Health has a 12-month low of $273.71 and a 12-month high of $458.75.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, topping the consensus estimate of $3.10 by $0.23. The company had revenue of $49.31 billion for the quarter, compared to analyst estimates of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.Elevance Health’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter last year, the firm earned $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, research analysts predict that Elevance Health will post 33.96 earnings per share for the current year.

Hedge Funds Weigh In On Elevance Health

Institutional investors and hedge funds have recently bought and sold shares of the business. Delta Investment Management LLC raised its holdings in shares of Elevance Health by 21.5% in the fourth quarter. Delta Investment Management LLC now owns 28,692 shares of the company’s stock valued at $10,058,000 after buying an additional 5,080 shares during the last quarter. Simplicity Wealth LLC grew its holdings in Elevance Health by 20.0% during the 4th quarter. Simplicity Wealth LLC now owns 1,220 shares of the company’s stock worth $428,000 after acquiring an additional 203 shares during the last quarter. Joel Isaacson & Co. LLC increased its position in Elevance Health by 45.1% in the 4th quarter. Joel Isaacson & Co. LLC now owns 2,561 shares of the company’s stock valued at $898,000 after acquiring an additional 796 shares in the last quarter. Pekin Hardy Strauss Inc. raised its stake in shares of Elevance Health by 448.0% in the fourth quarter. Pekin Hardy Strauss Inc. now owns 9,618 shares of the company’s stock worth $3,372,000 after acquiring an additional 7,863 shares during the last quarter. Finally, Keybank National Association OH lifted its position in shares of Elevance Health by 1.5% during the fourth quarter. Keybank National Association OH now owns 9,104 shares of the company’s stock worth $3,191,000 after purchasing an additional 132 shares in the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Key Stories Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q4 earnings beat consensus (EPS beat and strong profit print), which sparked an earlier rally and helped lift investor sentiment. Elevance Health (NYSE:ELV) Stock Price Up 6.3% on Strong Earnings
• Positive Sentiment: Leerink Partners nudged its price target up to $357 and maintained a “market perform” rating, a modest vote of confidence that signals upside potential from current levels. Leerink Partners adjusts price target on Elevance Health to $357
• Positive Sentiment: Consensus broker sentiment remains constructive (average “Moderate Buy”), which provides some support for the shares as analysts digest results and guidance. Elevance Health, Inc. Given Average Recommendation of “Moderate Buy”
• Neutral Sentiment: Company Q4 call and published highlights provide detail on membership shifts, margin dynamics and the drivers behind the quarter — useful for longer-term modeling but not a clear immediate catalyst. ELV Q4 2025 Earnings Call Highlights
• Negative Sentiment: Management forecast for 2026 profit came in below some Street estimates and flagged an anticipated revenue decline, which is the principal near-term headwind pressuring the stock. Elevance forecasts 2026 profit below estimates
• Negative Sentiment: Analysts and commentary highlighted margin pressures and membership shifts shaping a weaker 2026 outlook — narratives that have driven selloffs despite the quarterly beat. ELV Q4 Deep Dive: Margin Pressures and Membership Shifts
• Negative Sentiment: Regulatory context: a CMS proposal for only a modest Medicare Advantage rate increase added to near-term investor concern, contributing to a large negative move earlier in the week. Health Insurance Stock Could Rebound Off Historically Bullish Signal
• Negative Sentiment: Coverage pieces framed the results as “in line” but stressed the deteriorating outlook and ongoing industry headwinds, which has kept selling pressure on the shares after the initial post-earnings bounce. Elevance reports Q4 in line with expectations but stock drops

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.